Chemotherapy and hormonal therapy for endometrial cancers
GAO Yunong
Abstract：The objective of this essay is to conduct a critical appraisal of the published literature and clinical practices on the use of adjuvant chemotherapy and neo-adjuvant chemotherapy in the treatment of endometrial cancers.Chemotherapy is often recommended for high-risk subsets of stage Ⅰ disease.Level Ⅰ evidence exists for use of adjuvant chemotherapy in stage Ⅲ c endometrial cancer,although results of randomized trials have trials.Carboplatin plus paclitaxel is the current standard regimen,based on extrapolation of data from the metastatic setting.Neoadjuvant chemotherapy is performed followed by interval debulking for patients with poor performance status or those patients who the surgeon believes will have suboptimal debulking if surgery is attempted.Although hormonal therapy is not recommended in the adjuvant setting,it remains useful in the treatment of metastatic disease,particularly for tumors of low-grade endometrioid histology with a long time to recur.
Keywords：endometrial neoplasmchemotherapyneo-adjuvanthormonal therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 469-472 )